Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Germany just nailed the "Tango" Combo
OK, it's offtopic, but i'm proud!
Homepage newly updated
http://usfuelcorporation.com/
Freedom comes at a price
I hope, none of our friends became hurt!
F* storm
This is for you, my friends:
www.youtube.com/watch?v=8L0BxuqRXXwc
GLTA!
Please excuse my "Crystal Meth" Post...it was just a stupid joke, okay! I'm non able to answer private messages...but': I hope the Comp will be restarting up the german stock market....became deleted two years ago (but that occured to a several thousand Companies on the german market) There's not only the Frankfurt Stock Exchange, we also have Munich, Berlin Dusseldorf...but Frankfurt is surely the biggest...like Nyse. For me it's the last time, that im patient with our Comp. But for all of our long time buddies (like i am one of them) GLTA!!!
Always look on the bright side of life...whistle, whistle
We surely don't know, what could be coming, but after all those affort... there should be something "good"(hopefully) Things coming. Why keepin' up with all of those announcement's, when there's nothing in the bucket?
Wouldn't make any sense, or would' it?
Beside of all these gambling...
A merry (and early) christmas from germany to all of you, Fuel-Buddies!
I went in, four years ago, but now it seems, it could turn out to be a good Player in the near future. Let's (like always) be patient and see, what is happening. Can't be more worse than the nower pps
Best wishes from germany
"Stokki"
USFF was delisted on the german market, wich is an very unsatisfactory fact for us. The Company became Mails for several times, but didn't answer, how or if they would ever do any efforts do log on to the german markets again. And even germany (and switzerland) holds a plenty of shares, believe me!
Tom, may i ask for your opinion about the PPS, when they really build their first facility?
if you like to stay in contact with germany : usstocki@gmail.com best wishes to KY, keep it up for america...and don't let Romney rule...
Believe it or not, doc...i've already made some goulash soup, very tasty (6 hours of delay here) and things are keepin' on cooking There are still some of us germans folks who believe in this comp to succeed at the end! Certainly, I did have another opinion, a year ago (MLM was so kind to re-post it), but that has changed.Right now i would say, keep it up for american jobs and green energy, and give 'em a one year chance...wich should be the last! Only my opinion! Best wishes from germany, Stokki.
By the day KY coal is reaching germany, i will give it a big hand, by lighting candles at the runway It's quite interesting, USFF is working together with german companies, isn't it
Best wishes from germany, folks!
Welcome aboard PsD! Your journey has just begun! Interested in nothing but just ridiculous postings...so this is the right place to start! Even interested in self warming Towels? So that is the place to be! Some can offer u "keep on " postings, some may not. Some may say "keep your hands off"...but You, the Viewer may know, what's good for ...? Or if you're sent from high above...please tell our beloved USFF, to spread any information...even if the dog is sick or whatever....In behalf of some...
http://www.zoominfo.com/#!search/profile/person?personId=33435618&targetid=profile
Does anybody know what that means? "US Fuel International INC" in Arkansas? Or is it just meaningless crap?
Amen to that, Tom! I'd prefer St. Barth
"Form T" means late reported trade. After hour trade.
While Irene is now on her way to the east-coast i think in this situation we should forget about our different opinions on NSOL. I hope that nobody is getting injured! All the best wishes for you folks on the east side, take care of you. All the best wishes from germany, Stokki!
Hi Lilac! NL stands for Norman Lehrer, who left a quite strange posting here a while ago. This posting was deleted from this board, but you can still find a copy: http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_N/threadview?m=tm&bn=38949&tid=8817&mid=8817&tof=2&frt=2
Website update!
http://www.usfuelcorporation.com/
Happy independence day!
Hi Lilac, i also hope the comps "relaunch" is leading to some good news. I'm also one of the longs, as i would say. I went in on Dec. 2009. That's also a long time. So good luck for all of us!
NSOL Website offline. The old link leads to http://www.usfuelcorporation.com/ (by now it's under costruction, but it's early in the morning). So let's see what's happening. tom8oes was right!
http://finance.yahoo.com/news/...From-pz-3161127310.html?x=0&.v=1
Tesetaxel Results From Multiple Dose-Ranging Clinical Trials Updated at ASCO
tweet
Email
Print
Press Release Source: Genta Incorporated On Wednesday June 8, 2011, 8:40 am
-- Safety of weekly dosing schedule provides "dose-dense" option
-- Low incidence of neuropathy despite extended therapy
-- Published and ongoing combination trials with capecitabine (Xeloda(R))
BERKELEY HEIGHTS, N.J., June 8, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA - News) announced updated results from multiple dose-ranging trials of tesetaxel, the leading oral taxane in clinical development. Together, the trials show a consistent and predictable safety profile along with clinical activity used alone or combination with capecitabine (Xeloda(R); Hoffman LaRoche, Inc.), the leading oral fluoropyrimidine used in patients with breast cancer and gastric cancer. Updated results, published in conjunction with the 2011 annual meeting of the American Society of Clinical Oncology (ASCO), are summarized as follows:
Three Phase 1 studies of tesetaxel administered as a single agent have been completed. Together, these trials show that 27 mg/m2 is a safe starting dose, and that subsequent doses can be escalated to 35 mg/m2 depending upon individual patient tolerance. The principal adverse reaction has been neutropenia. Hypersensitivity reactions have not been observed.
Two studies (one completed, one ongoing) have examined the safety, dosing and pharmacokinetics of tesetaxel administered in combination with capecitabine. The completed study, which showed no adverse drug interactions or difference in pharmacokinetics when the drugs were co-administered, was recently published. An abstract of this new report is available here: http://www.ncbi.nlm.nih.gov/pubmed/21547572.
Ongoing dose-ranging studies include:
A trial of tesetaxel plus capecitabine administered at the maximally tolerated dose of both agents. The use of this combination is envisioned for future clinical trials, and completion of accrual is expected in June 2011.
A study of tesetaxel in combination with cisplatin and capecitabine as initial therapy for patients with gastric cancer.
A dose-ranging study of tesetaxel (24 to 31 mg/m2 every 3 weeks) in Japanese subjects.
A study of tesetaxel administered weekly for 3 consecutive weeks -- currently open to accrual at a total dose of 45 mg/m2.
"In aggregate, this broad program confirms the tolerable safety profile established using tesetaxel alone or in combination," said Dr. Raymond P. Warrell, Jr., Genta's Chief Executive Officer. "We continue to expand the profile of tesetaxel use in combination with drugs that comprise the standard-of-care in gastric cancer and breast cancer, our priority indications. Early clinical data suggest confirmation of preclinical data that tesetaxel can overcome standard mechanisms of clinically acquired taxane resistance. The lack of hypersensitivity and significant nerve damage -- coupled with flexible dosing, elimination of premedication requirements, and high levels of patient convenience -- offer important advantages that we are exploring in ongoing trials."
About Tesetaxel
Unlike standard taxanes that must be administered intravenously, tesetaxel is a capsule that is taken by mouth. Compared with the standard agents, clinical and preclinical data show that tesetaxel:
Is active in diseases that are resistant to standard taxanes
Is not associated with serious (occasionally fatal) hypersensitivity reactions
Eliminates requirements for premedication (e.g., steroids, antihistamines, etc.)
Reduces damage to peripheral nerves
Offers flexible and convenient dosing for patients
Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has been evaluated in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials. The Company has announced that gastric (stomach) cancer will be the lead indication for Phase 3 registration studies. A second portfolio compound, Genasense(R) (oblimersen sodium) Injection, is a modified DNA-based antisense drug that may enhance the effectiveness of anticancer therapy. The Company has recently announced that a randomized trial of Genasense did not increase overall survival in patients with advanced melanoma. Genta is exclusively marketing Ganite(R) (gallium nitrate injection) in the U.S, which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite(R) that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipate", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:
the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
the safety and efficacy of the Company's products or product candidates;
the timing of commencement and completion of any clinical trials;
the Company's assessment of its clinical trials;
the Company's ability to develop, manufacture, license, or sell its products or product candidates;
the Company's ability to enter into and successfully execute any license and collaborative agreements;
the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the risk of bankruptcy;
the adequacy of the Company's patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2011 and its most recent quarterly report on Form 10-Q.
Contact:
Genta Investor Relations
info@genta.com
Media Contact
908-286-3980
And even "teutonic stokki", the lil' german investor is meanwhile dissapointed and f* angry. But believe me, folks here also treated me like an idiot! And they still do! God bless you all.
Weel, getting my money back would be already a good news for me But if that ever should happen, i'm afraid it will take it's time. So i have to wait, like the most of us.
You may cry on my shoulders
But we've got to take a look on what's next after R/S.
I think we already know the answer. But, believe me there are things even more worse then Genta, like NSOL The worst sh* i've ever seen). Will write you tomorrow, gotta go to bed here in germany, shift is starting early at 5:30 am.
I don't think there will be any good news about this comp. Beside of: "Closed". I'm not an Idiot, believe me
No trade today, my love has gone away
The bottle stands for lorn, a symbol of the dawn
No trade today, it seems a common sight
But people passing by don't know the reason why
Don't take it to serious, guys!
What's up?
No cheers, no bashers?
I've never seen so many bashing and pumping theories, as it is here I think, it's just okay to wait til ASCO and then we will see the results. Some may be in for pocket money, are you gambling for 23 $? If that's the fact, i can understand you. But if you've done a serious invest, it would be good to wait a while...'til ASCO. This is also the way my folk is doing it, we just have 8%(max) of your average share change per day!!
A lot of people here are telling, that all this here is a scam. But why should anybody be so stupid to by it at 0,035$, even if it is on a low level?
BTW: The end of the world is funny thing. If you take a look on youtube you will find the the most bad theories about that sh*, like the mayan calendar ends on Dec., 21th, 2012
I think it has a chance, and even the german traders are thinking that way, the only question is, when there will be a rebound. We've all got to have some patience. If it gears up to 0,1 § some of us will have their first deals, while some of us who went in before lost nearly everything they own. That's the way it works, either in US or in Germany, or maybe elsewhere. But theres no way to change it.
New 8K Filing!
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001116112%2D11%2D000018%2Etxt&FilePath=%5C2011%5C05%5C18%5C&CoName=NUCLEAR+SOLUTIONS+INC&FormType=8%2DK&RcvdDate=5%2F18%2F2011&pdf=
FFI gets a new projectmanager. Begins to get interesting!
Amarkiii, WTF is going on, you're not going to quit? I'm learning your language, so you can't be out. The more i learn, the more funny my postings can get Ich bin ein Berliner
And that's damn f..right.
Greetings from the german Clown
I am still willing to wait. And even i am one of the "longs", believe me! But even i am holding out 'til the "end". I still think there's a big deal for NSOL/FFI to be made in the future! So let's keep faith. And i'm shure there will be some good news within the next 2 month. Just a feeling, no suggestion.
I don't think that there will be a big rush on Monday. But there will be a very big bang in june, when Genta is spreading some good news at the ASCO!
I don't think that there will be a big rush on Monday. But there will be a very big bang in june, when Genta is spreading some good news at the ASCO!